Vicebio
ExitedVicebio is a clinical-stage biopharmaceutical company developing transformative multi-pathogen vaccines for respiratory viral infections.
London, UKwww.vicebio.com ↗
Total raised
€0
€0
Funding rounds
0
Investors
0
distinct backers
Active since
—
Funding rounds
0 roundsNo funding rounds recorded.
Exit
Type
acquisition
Date
Jul 2025
Value
€1.4B
Acquiror
Sanofi (France)